
Kalluri Laboratory
Principal Investigator: Raghu Kalluri, M.D., Ph.D.
Frederick F. Becker Distinguished University Chair | Professor and Chairman, Department of Cancer Biology | Director, Metastasis Research Center
Areas of Research
- Cancer Biology
- Tumor Microenvironment
- Cancer Metastasis
- Fibrosis
- Angiogenesis
- Tissue Engineering
- Drug Development
Welcome to the Kalluri Laboratory at the University of Texas MD Anderson Cancer Center. We investigate why and how cancer initiates and progresses with an implicit goal to develop new strategies for early detection and impactful treatments. The Kalluri Lab is credited with numerous fundamental contributions in the fields of matrix biology, regenerative medicine and extracellular vesicles biology as it relates to fibrotic diseases and cancer.
Scroll Ahead
- Departments, Labs and Institutes
- Labs
- Kalluri Laboratory
Research Focus Areas
Cancer Biology and Metastasis
Tumor Microenvironment
Tissue Injury and Regeneration
Extracellular Vesicles in Health and Disease
Tissue Health and Aging
Our Goal
We perform innovative and cutting-edge research to unravel how cells and their environment communicate to maintain organ health and how such communication networks in tissues are altered in cancer and other diseases.
Meet the Team
Learn about the Kalluri Lab members
Our Approach
Experimental Laboratory Research
The Kalluri Laboratory employs the latest cellular and molecular biology techniques, including single cell RNA sequencing, spatial transcriptomics and proteomics, super resolution microscopy, advanced cell sorting methods, immunological analysis, flow cytometry, genetic analysis, and nanoimaging. We utilize various pre-clinical models and are a leading laboratory for generation and use of genetically engineered mouse models of cancer for advancement of detection and treatment.
Sample publications:
Mahadevan KK, Dyevoich AM, Chen Y, Li B, Sugimoto H, Sockwell AM, McAndrews KM, Sthanam LK, Wang H, Shalapour S, Watowich SS, Kalluri R. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science. 2024 Jun 28;384(6703):eadh4567. PMID: 38935717.
Zhou X, LeBleu VS, Fletcher-Sananikone E, Kim J, Dai J, Li B, Wu CC, Sugimoto H, Miyake T, Becker LM, Volpert OV, Lawson E, Espinosa Da Silva C, Patel SI, Kizu A, Ehsanipour EA, Sha D, Karam JA, McAndrews KM, Kalluri R. Vascular heterogeneity of tight junction Claudins guides organotropic metastasis. Nat Cancer. 2024 Sep;5(9):1371-1389. PMID: 39289595.
McAndrews KM, Chen Y, Darpolor JK, Zheng X, Yang S, Carstens JL, Li B, Wang H, Miyake T, Correa de Sampaio P, Kirtley ML, Natale M, Wu CC, Sugimoto H, LeBleu VS, Kalluri R. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL-6 Mediated Therapy Resistance in Pancreatic Cancer. Cancer Discov 12(6):1580-1597, 6/2022. PMID: 35348629.
Chen Y, Yang S, Tavormina J, Tampe D, Zeisberg M, Wang H, Mahadevan KK, Wu CJ, Sugimoto H, Chang CC, Jenq RR, McAndrews KM, Kalluri R. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. 2022 Aug 8;40(8):818-834.e9. PMID: 35868307.
Computational Biology and Bioengineering
The Kalluri Laboratory is developing new diagnostic and therapeutic tools and leverages artificial intelligence and bioinformatics approaches. Our laboratory includes full-time computational biologists, applied mathematicians and software developers who support our omics data analysis and integration, medical device/algorithm development, AI-based image analysis, digital biology, and AI-driven bioengineered drug development efforts.
Sample Publications:
Li B, Kugeratski FG, Kalluri R. A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes. eLife, 2024, 10.7554/eLife.90390.3. PMID: 38529947.
Kugeratski FG, Hodge K, Lilla S, McAndrews KM, Zhou X, Hwang RF, Zanivan S, Kalluri R. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat Cell Biol 23(6):631–641, 6/2021. PMID: 34108659.
Kapoor KS, Kong S, Sugimoto H, Guo W, Boominathan V, Chen YL, Biswal SL, Terlier T, McAndrews KM, Kalluri R. Single Extracellular Vesicle Imaging and Computational Analysis Identifies Inherent Architectural Heterogeneity. ACS Nano. 2024 May 7;18(18):11717-11731. PMID: 38651873.
Bench-to-Bedside Translation
The Kalluri Laboratory is translationally-focused and many of its discoveries have seen clinical implementation. Fundamental discoveries from our laboratory are advanced to pre-clinical testing and first-in-human clinical trials, all within MD Anderson. The laboratory collaborates closely with colleagues at the primate facility and in our clinical care departments.
Sample Publications:
Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszalek JR, Maitra A, Yee C, Rezvani K, Shpall E, LeBleu VS, Kalluri R. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3(8), 4/2018. PMCID: PMC5931131.
Kapoor KS, Harris K, Arian KA, Ma L, Schueng Zancanela B, Church KA, McAndrews KM, Kalluri R. High throughput and rapid isolation of extracellular vesicles and exosomes with purity using size exclusion liquid chromatography. Bioact Mater. 2024 Sep 4;40:683-695. PMCID: PMC11407901.
Luo X, McAndrews KM, Arian KA, Morse SJ, Boeker V, Kumbhar SV, Hu Y, Mahadevan KK, Church KA, Chitta S, Ryujin NT, Hensel J, Dai J, Dowlatshahi DP, Sugimoto H, Kirtley ML, LeBleu VS, Shalapour S, Simmons JH, Kalluri R. Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity. J Control Release. 2024 Oct;374:550-562. PMID: 39146981.
Surana R, LeBleu VS, Lee JJ, Smaglo BG, Zhao D, Lee MS, Wolff RA, Overman MJ, Mendt MC, McAndrews KM, Yang S, Rezvani K, Kalluri R, Maitra A, Shpall EJ Pant. Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation. JCO 40, TPS633-TPS633(2022). DOI:10.1200/JCO.2022.40.4_suppl.TPS633.
Smaglo BG, LeBleu VS, Lee JJ, Maitra A, Kalluri R, Rezvani K, Solis Soto LM, Hurd M, Kaur I, Mendt Vilchez MC, Kirtley ML, Shaftoe SL, Morelli MP, Overman MJ, Zhou D, Wolff RA, Tu J, Willis JA, Huey RW, Lee MS, Bhosale PR, Dworsky SW, Xu L, Pant S, Shpall EJ; Abstract C084: iExplore: A phase I study of mesenchymal stem cell derived exosomes with KrasG12D siRNA for metastatic pancreas cancer patients harboring the KrasG12D mutation. Cancer Res 15 January 2024; 84 (2_Supplement): C084. https://doi.org/10.1158/1538-7445.PANCA2023-C084.
Training in the Kalluri Laboratory
Learners from a variety of academic backgrounds including experimental biology, medicine, computational biology, computer science, physics, mathematics, bioinformatics, and engineering complete their training in the Kalluri Laboratory.
Training and mentorship are core commitments of the lab. We advise trainees at all career stages, and research opportunities at the undergraduate, graduate and postdoctoral levels are available in the Kalluri Laboratory.
Training and mentorship are core commitments of the lab. We advise trainees at all career stages, and research opportunities at the undergraduate, graduate and postdoctoral levels are available in the Kalluri Laboratory.
Contact the Kalluri Laboratory
We are located in the Department of Cancer Biology at MD Anderson Cancer Center. Visit us at our Texas Medical Center campus or follow along on social media.